Apollon’s ambition is to become the premier global medical cannabis company legally licensed to develop successful personalised clinical treatments utilising artificial intelligence on clinical trial patient data.
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview</td>
<td>04</td>
</tr>
<tr>
<td>The Medical Cannabis Market</td>
<td>09</td>
</tr>
<tr>
<td>Our Focus on Cancer Treatments</td>
<td>12</td>
</tr>
<tr>
<td>Test Results</td>
<td>13</td>
</tr>
<tr>
<td>Operations in Jamaica</td>
<td>15</td>
</tr>
<tr>
<td>Products</td>
<td>18</td>
</tr>
<tr>
<td>Summary</td>
<td>21</td>
</tr>
<tr>
<td>Appendix</td>
<td>25</td>
</tr>
</tbody>
</table>
ABOUT APOLLON

Apollon Formularies is an international medical cannabis pharmaceutical company specialising in cutting edge research and development enabling the unique legal treatment of patients with cancer and chronic pain.

Apollon’s operations are federally legal and licenced by the Cannabis Licensing Authority (CLA) in Jamaica. It holds a suite of CLA licenses which allow the company to work with full/broad spectrum oils inclusive of high levels of THC.

Apollon medical cannabis formulations are currently available by prescription to all licensed Jamaican physicians for their patient treatments and for export to jurisdictions allowing legal import of medical cannabis and where the use of medical cannabis has been legalised.

Apollon is a publicly traded company listed on the Aquis Growth Market in London (AQSE: APOL).
OUR FOCUS

Cancer
Apollon’s proprietary medical cannabis formulations have proven to kill breast and prostate cancer cells at a rate of nearly 100%, as demonstrated by recent third-party independent pre-clinical 3D cell culture laboratory data at BIOENSIS laboratories.

Chronic Pain
The National Academy of Science 2017 Report cited conclusive or substantial evidence that cannabis and/or cannabinoids are effective for the treatment of chronic pain in adults.

THC
THC is known for its psychoactive properties, but this cannabinoid has also proven to be an ideal treatment for pain. High THC formulations can also be especially useful for patients in palliative care and cancer treatments. For other medical conditions that require extreme potency, large quantities of THC can be an effective tool for providing comfort and relief under the supervision of a licensed physician.

Palliative Care
The last days and hours of a person’s life can be associated with immense physical as well as emotional suffering. Medical cannabis may be of value for a number of conditions related to palliative care including but not limited to pain, nausea and vomiting, depression, anxiety and appetite stimulation.
REVENUE STREAMS

CURRENT REVENUE STREAMS

- In & out-patient treatment and consultations
- Apollon Dispensary Sales in Jamaica
- Sales of wholesale bulk cannabis oils
- Third party tolling fee from extraction & refining
- White label sales under specific licence agreements

FUTURE REVENUE STREAMS

- Export of Apollon oil and products to wider markets
- Licensing revenue from 3D printer technology
- Sales and royalties generated from proprietary formulations
- Expansion of global treatment facilities
- Revenue from Joint Venture arrangements
OUR BOARD

Stephen D. Barnhill, MD, BCLD | Chairman & CEO
A physician trained in Laboratory Medicine and Board Certified by the American Board of Bioanalysis. His patents were part of the intellectual property portfolio that won 1st Place out of 1,600 and was awarded the MICO award from MDB Capital for the most disruptive intellectual property portfolio. Inventor on more than 40 patents (US and International). Former Chairman and CEO of both private and publicly traded Biotech companies.

Nicholas F. Barnhill (Nick) | Director
As the Director of Operations and Cultivation Knowledge of AFI, he is responsible for providing general business direction and management oversite of the company’s medical cannabis industry initiatives including: the procurement of licenses, and the establishment of lawful, quality production capabilities. He is involved in the supervision and accomplishment of certain cultivation and operational objectives involving the growth and procurement of raw materials and the establishment of facilities for medical cannabis production in Jamaica. As the Director of Cultivation of AFJ Mr. N. Barnhill has been supervising all phases of the company’s cultivation operations including: regulatory compliance to CLA standards and law regarding production, quality control, maintenance, receiving, storage and shipping.
Kevin Sheil | Director

A capital markets veteran with over 30 years’ experience, Mr. Sheil has experience across a number of sectors. Kevin has worked as a consultant to an AI technology firm, providing valuable input as Apollon continues to grow its line of AI-determined patient specific cannabis medicines and commercialise its unique 3D Pharmaceutical Printer. Mr. Sheil was a telecom sector specialist with Barclays, Credit Suisse and then Citibank where he worked for over 10 years and was consistently in the top rankings in Extel & Institutional Investor surveys. Mr Sheil worked as Head of Multi-Product Sales at Citibank and was responsible for broking all equity-based products as well as fixed Income into institutional accounts. Mr Sheil has also spent over nine years as a general equity fund manager for Trium Capital Managers.

Nick Ingrassia | Director

Nicholas is an oil & gas executive with over 19 years’ experience across a wide range of corporate roles in-and-around the oil & gas industry including M&A, business development, financing, commercial, investor relations and operational functions. Nicholas started his career in banking with roles at Morgan Stanley (energy investment banking) and RBS (structured energy lending & debt advisory) before joining the oil & gas industry working for AIM-listed Valiant Petroleum plc, LSE-listed Salamander Energy plc and AIM-listed Faroe Petroleum Plc. Nicholas is currently Business Development Director and member of the executive team at AIM-listed Longboat Energy plc. He has MA Hons degree from the University of St Andrews in Ancient History.
The Medical Cannabis Market: Global

Until recently, the global medical cannabis market has been dominated by North America.

In the last few years, European countries have reformed their laws around medical cannabis causing the global market to boom.

Previously valued $5 billion in 2018, the market now is expected to reach over $59 billion by 2025, growing at a CAGR of 29.7% from 2019.
THE MEDICAL CANNABIS MARKET: EUROPE

The European medical cannabis market is the second largest market globally, behind the US, and is expected to reach over $3 billion by 2025, growing at a CAGR of 17.1% from 2020.

With the population of Europe set at double that of the US, there is also significant upside to the market and potential future revenue streams.
OUR FOCUS
ON CANCER TREATMENTS

• Cancer is a leading cause of death worldwide

• In 2020, global oncology spending totalled $167 billion

• In the US, at an average total of $150,000, cancer treatment costs are more than four times higher than treatment for other common health conditions

• Cost of mainstream treatment is prohibitively expensive, especially for those living in developing countries

• Breast and prostate cancer are two of the most common types of cancer and among the top five costliest to treat
Apollon has successfully proved that its medical cannabis formulations were effective in killing HER2+ breast cancer cells, triple negative breast cancer cells (TNBC) as well as hormone-resistant and hormone-sensitive prostate cancer cells, all in 3D cell cultures by third party independent laboratory testing carried out by US-based BIOENSIS.

Both breast cancer and prostate results were conducted under a joint testing agreement with Aion Therapeutic Inc.

If successful in upcoming patient treatments, Apollon’s medical cannabis formulations have the very real potential to be used on a complimentary basis with existing conventional medication or as an alternative to mainstream medication, providing better patient outcomes.
ABOUT BIOENSIS

- BIOENSIS is a US based pre-clinical testing laboratory
- It is the solution of choice of predictive pharmacology needs led by a scientific team with more than 40 years of combined experience in preclinical pharmacology
- The Company is the premiere innovator of 3D pharmacology technologies that more accurately recapitulate the microenvironment of human tissues and tumours
- BIOENSIS is routinely used by large pharmaceutical companies to independently verify their formulations
- They have a demonstrated track record of unparalleled commitment to and collaboration with customers to achieve their predictive pharmacology objectives
**OUR LICENCES**

Apollon Formulaires Jamaica Limited ("Apollon Jamaica") is licensed to operate at the Federal level in Jamaica and hold the following licences and approvals:

- Research and Development Licence (Experimental)
- Retail Licence (Therapeutic)
- Processing Licence
- Cultivation (R&D)
- Export (Based on the above licences)

Together these licences create a vertically integrated full spectrum (inclusive of THC) medical cannabis company both in Jamaica and to the international market via legal export from Jamaica to jurisdictions where the law allows import of medical cannabis products.

Apollon Formulaires Jamaica is licensed to operate at the Federal level in Jamaica and holds the following licences:

- Human Research & Development
- Cannabis Cultivation
- Retail Dispensary
- Retail Therapeutic
- Processing
OUR OPERATIONS

Medically Supervised Treatments
Apollon’s CLA Research and Development Licence allows for physician supervised medical cannabis treatments under the direction of the Ministry of Health (MoH).

Apollon has a full team of licensed Jamaican medical doctors specialising in oncology, palliative care, chronic pain, neurosurgery, surgery and general wellness with additional expertise in treating patients with Apollon medical cannabis products which are available in Jamaica by prescription only.

Use of Artificial Intelligence
Apollon uses the latest state-of-the-art artificial intelligence techniques to optimize strain genetics for medical cannabis formulation development and to analyse patient genomic data to identify new potential biomarkers to triage patients into the correct treatment protocols.

Processing & Extraction
Apollon’s CLA licensed Processing Laboratory is based in Negril, Jamaica. This state-of-the-art medical cannabis processing facility produces medical quality full spectrum cannabis oil (inclusive of THC). Apollon recently won the prestigious Jack Herer Cup 1st Place for Best Oil (solvent) which was produced in our Negril laboratory.
**OUR FACILITIES**

**Apollon Negril Facility**
This facility has been utilised since 2015 to provide in-patient and out-patient medical cannabis treatments for use by patients needing access to prescribed medical cannabis

Apollon has treated in excess of 400 patients in the last 24 months at this facility

Apollon’s R&D and processing laboratory, as well as its licenced dispensary, are also based within its Negril facility

**International Cancer Institute, Kingston**
In July 2021, Apollon secured a long-lease for its first International Cancer Institute in Kingston, Jamaica

It specialises in Complementary and Alternative Medical (CAM) treatments for cancer patients

Dr. Spence, a licensed Jamaican physician specialising in Clinical Oncology, Radiation Therapy, and Palliative Care Medicine, has been appointed as Medical Director of the facility

Apollon to commence patient treatment in Q3 2021
TRADEMARKED PRODUCTS

Apollon has created proprietary hybrid pharmaceutical medical cannabis strains, technology, formulations, and treatment products including:

Apollon capsules - 33mg of CBD and THC at a 12:1 ratio

Apollon oral spray - 750mg of CBD in addition to THC, CBG, and CBC

Apollon vape pen - full extract cannabis oil containing 70% CBD and 5% THC
These formulations were created from information gathered from Apollon’s proprietary artificial intelligence techniques and include:
**KEY MILESTONES**

**April 2014**
- Expands operations to Jamaica.

**June 2015**
- Apollon Formularies created by Dr. Stephen Barnhill and his family in order to help cancer patients globally with medical cannabis as it helped his mother who suffered with pancreatic cancer.

**November 2016**
- Apollon Negril Facility opens for cancer patients using Apollon medical cannabis.

**September 2019**
- Establishes Pharmaceutical Processing Laboratory.

**November 2018**
- Apollon Receives Cannabis Licence Authority (CLA) Conditional Approval for cultivation, processing, research and development for manufacturing medical cannabis products and treating cancer patients.

**November 2019**
- Apollon medical proprietary cannabis treatment formulations tested by 3rd party independent laboratory testing at BIOENSIS with results expected in early 2021.

**April 2021**
- Expands to Europe and becomes one of the first publicly listed medical cannabis companies on the Aquis exchange in London licenced to have high THC prescription medical products (AGSE:APOL).

**June 2021**
- Joint testing by BIOENSIS has revealed combined formulations with Aion Therapeutics Inc. are effective in killing HER2+ breast cancer cells grown in 3D cell culture.

**May 2021**
- Joint testing by BIOENSIS has revealed combined formulations with Aion Therapeutics Inc. are effective in killing prostate cancer cells grown in 3D cell culture.

**July 2021**
- Signs the lease for Apollon International Cancer Institute for Complementary and Alternative Medicine (CAM), in Jamaica.

---

Corporate milestones

Intellectual achievements
NEAR TERM GOALS

Commence human treatments on breast cancers and prostate cancer patients
Opening of Apollon International Cancer Institute
Expansion of production facility in Negril
Expand large scale clinical trials to other forms of cancer
Apply for patent protection on all propriety formulations shown to be effective in preliminary results
Expand product line to entire Jamaican dispensary network
Look to sign export agreement into key jurisdictions
INVESTMENT CASE

- Established business
- Multiple revenue streams
- Extensive clinical data
- Patent pending products
- Trademarked formulations
- Validation through independent testing
CONTACTS

**APOLLON**

**Stene Jacobs:**
stene@apollon.org.uk
Chief Operating Officer

**Dr. Stephen Barnhill**
stephen@apollon.org.uk
Chairman Apollon Formularise Ltd

**Kevin Sheil:**
kevin@apollon.org.uk
Director Apollon Formularies Ltd

**BLYTHWEIGH (Financial PR)**

**Megan Ray**
megan.ray@blytheweigh.com

**Alice McLaren**
alice.mclaren@blytheweigh.com

www.apollon.org.uk
MANAGEMENT TEAM

Stephen D. Barnhill, MD, BCLD | Chairman & CEO
A physician trained in Laboratory Medicine and Board Certified by the American Board of Bioanalysis. His patents were part of the intellectual property portfolio that won 1st Place out of 1,600 and was awarded the MICO award from MDB Capital for the most disruptive intellectual property portfolio. Inventor on more than 40 patents (US and International). Former Chairman and CEO of both private and publicly traded Biotech companies.

Nicholas F. Barnhill (Nick) | Director
As the Director of Operations and Cultivation Knowledge of AFI, he is responsible for providing general business direction and management oversite of the company’s medical cannabis industry initiatives including: the procurement of licenses, and the establishment of lawful, quality production capabilities. He is involved in the supervision and accomplishment of certain cultivation and operational objectives involving the growth and procurement of raw materials and the establishment of facilities for medical cannabis production in Jamaica. As the Director of Cultivation of AFJ Mr. N. Barnhill has been supervising all phases of the company’s cultivation operations including: regulatory compliance to CLA standards and law regarding production, quality control, maintenance, receiving, storage and shipping.
Kevin Sheil | Director

A capital markets veteran with over 30 years’ experience, Mr. Sheil has experience across a number of sectors. Kevin has worked as a consultant to an AI technology firm, providing valuable input as Apollon continues to grow its line of AI-determined patient specific cannabis medicines and commercialise its unique 3D Pharmaceutical Printer. Mr. Sheil was a telecom sector specialist with Barclays, Credit Suisse and then Citibank where he worked for over 10 years and was consistently in the top rankings in Extel & Institutional Investor surveys. Mr Sheil worked as Head of Multi-Product Sales at Citibank and was responsible for broking all equity-based products as well as fixed Income into institutional accounts. Mr Sheil has also spent over nine years as a general equity fund manager for Trium Capital Managers.

Nick Ingrassia | Director

Nicholas is an oil & gas executive with over 19 years’ experience across a wide range of corporate roles in-and-around the oil & gas industry including M&A, business development, financing, commercial, investor relations and operational functions. Nicholas started his career in banking with roles at Morgan Stanley (energy investment banking) and RBS (structured energy lending & debt advisory) before joining the oil & gas industry working for AIM-listed Valiant Petroleum plc, LSE-listed Salamander Energy plc and AIM-listed Faroe Petroleum Plc. Nicholas is currently Business Development Director and member of the executive team at AIM-listed Longboat Energy plc. He has MA Hons degree from the University of St Andrews in Ancient History.
Dr Anthony Hall MD, MDCM, FACS, FAAN | Consultant

Dr Hall is a Neurosurgeon, Board-Certified and Fellowship Trained in brain and spine surgery. He has been practicing medicine for over 25 years. He earned his Doctor of Medicine degree from McGill University Faculty of Medicine and one of the first five physicians Certified by the state of Florida to recommend medical cannabis. Dr Hall has pioneered, developed, and practiced minimally invasive and endoscopic surgical techniques for the brain and spine since 1993. He has performed research in spinal electrophysiology at the University of Miami as part of the Miami Project to Cure Paralysis. Dr Hall has faculty appointments at Nova Southeastern University College of Medicine and the Herbert Wertheim Florida International University College of Medicine. Dr Hall has also lectured and taught students from Barry University and the University of Alabama. He is the President-Elect of the Miami-Dade Chapter of the National Medical Association, and he is also a member of the Congress of Neurological Surgeons, American Association of Neurological Surgeons, and the Florida Neurosurgical Society. Dr. Hall is actively involved with outreach programs and performs charity medical care in several countries.
ADVISORY BOARD

Dr. Alfred Dawes MBBS DM FACS | Consultant
Dr Dawes is a General Surgeon with additional expertise in Bariatics with a fellowship in Bariatics and Minimally Invasive Surgery at the Santa Casa Hospital in Curitiba, Brazil. From 2012-2015 he worked at the Spanish Town Hospital as a Senior Registrar in General Surgery and was Senior Medical Officer at the Savanna-La-Mar Public General Hospital. Dr Dawes is a Fellow of the American College of Surgeons (FACS).

Dr. Herb Fritsche PH.D | Consultant
Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years. He has published over 200 peer-reviewed scientific papers, invited articles and book chapters. Dr Fritsche served as a consultant to the National Cancer Institute (NCI), the Expert Panel for developing Tumour Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center, the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, and the Editorial Board of six international scientific journals. He was awarded the Johnson & Johnson Award for Outstanding Research & Contributions to Clinical Biochemistry, the Abbott-ISOBM Award for Outstanding research in oncology the and the Morton K Schwartz Award for Outstanding Cancer Research.
INDEPENDENT TESTING OF CANCER FORMULATIONS

All the medical cannabis formulations using in independent testing were developed by Apollon Formularies Jamaica Limited.

It was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) (“Aion”), a BC based international pharmaceutical company trading on the Canadian Securities Exchange.

Authorized in accordance with Apollon Jamaica’s Research & Development licence issued by the Jamaican government’s Cannabis Licensing Authority (CLA).

What is 3D Cell Culture?
A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions. Unlike 2D environments, a 3D cell culture allows cells in vitro to grow in all directions, similar to how they would in the body.
JAMAICAN REGULATORY ENVIRONMENT

The Cannabis Licensing Authority (CLA), an agency of the Ministry of Industry, Commerce, Agriculture and Fisheries, was established in 2015 under the Dangerous Drug (Amendment) Act, (DDA) with a specific role to establish and regulate Jamaica’s legal ganja and hemp industry.

- Strengthening the capacity and programs of the NCDA
- Strengthening Jamaica’s mental health institutions
- Funding scientific and medical research into ganja and hemp
- Supporting the regulatory arrangements of the CLA
Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica and a contractual affiliate of Apollon. Apollon Jamaica is licensed by the Jamaican government’s Cannabis Licensing Authority (CLA) to purchase cannabis under tripartite agreements from licensed cultivators, process, perform research and development, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision.

Apollon holds a 49% interest in the issued share capital of AFJ, a limited corporation existing under the laws of Jamaica, and is entitled to 95% of the net profit of the business of AFJ. In addition to such interests and rights as described above, AFJ currently has several strategic partnerships in place to fulfil the mission of creating an all-encompassing, worldwide medical cannabis corporation that can satisfy the growing global market for legal, medical cannabis treatment in Jamaica and for the formulations of, and access to, pharmaceuticals and nutraceuticals that include legal, medical cannabis for sale in Jamaica and eventually such other countries to which export/import of medical cannabis will be permitted or where medical cannabis can be lawfully cultivated, processed and/or sold locally.